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We assessed the prevalence of Streptococcus pneumoniae serotypes in the nasopharynx of healthy children,
antimicrobial susceptibility patterns, risk factors for carriage, and the coverage of heptavalent pneumococcal
conjugate vaccine. In 2,799 healthy infants and children, the S. pneumoniae carrier rate was 8.6% (serotypes 3,
19F, 23F, 19A, 6B, and 14 were most common). Most pneumococci (69.4%) were resistant to one or more anti-
microbial classes. The rate of penicillin resistance was low (9.1%); macrolide resistance was high (52.1%).
Overall, 63.2% of the isolates belonged to strains covered by the heptavalent pneumococcal vaccine. This per-
centage was higher in children <2 years old (73.1%) and in those ages 2-5 years (68.9%). Sinusitis in the previ-
ous 3 months was the only risk factor for carrier status; acute otitis media was the only risk factor for the carriage
of penicillin-resistant S. pneumoniae. Most isolated strains are covered by the heptavalent conjugate vaccine,
especially in the first years of life, suggesting that its use could reduce the incidence of pneumococcal disease.
he nasopharynx of children has resident microbial flora
that do not usually harm the child but, in some cases, con-
stitute a reservoir of pathogens implicated in respiratory tract
infections and invasive diseases (1,2). The bacteria carried in
the nasopharynx of healthy children reflect the infection-caus-
ing strains currently circulating in the community (3), and so
studies of the prevalence of different pathogens and their resis-
tance patterns can provide useful indications for more rational
therapeutic and preventive strategies. 
The asymptomatic nasopharyngeal carriage of Streptococ-
cus pneumoniae is widely prevalent in young children and has
been related to the development of disease and the spread of
the pathogen (4,5); furthermore, nasopharyngeal colonization
by antibiotic-resistant S. pneumoniae has steadily increased
over the last few years (6,7). Antibiotic-resistant strains are
more often carried by infants and young children than adults and
belong to a limited number of serotypes that are also some of the
most common causes of invasive pediatric diseases (8-10). 
A heptavalent conjugate vaccine, which includes the most
common serotypes involved in invasive diseases, effectively
induces protection against pneumococcal nasopharyngeal car-
riage (11,12). However, while the vaccine is statistically effec-
tive in preventing carriage of vaccine-related strains, a number
of reports show an increase in the percentage of nonvaccine
strains in immunized patients (13,14).
We assessed the prevalence of different S. pneumoniae
serotypes in the nasopharynx of healthy children attending
day-care centers and primary schools, determined their
antimicrobial susceptibility to a wide range of therapeutic
compounds, identified the risk factors for carrier status, and
defined the possible coverage provided by the heptavalent
pneumococcal conjugate vaccine during the first years of life.
Patients and Methods
Study Population
From April 15 through June 15, 2000, a single nasopharyn-
geal specimen per child was obtained from children attending
day-care centers and the first years of primary schools in 13
Italian cities (3 northern, 4 central, 6 southern). Only one pedi-
atrician, belonging to the main pediatric department in each
city, was responsible for the study. Two day-care centers (one
for infants and children <3 years of age and one for children
ages 4-5 years) and one primary school (children ages 6-7
years) were also included. All of the children attending each
participating center were considered eligible unless they had
an underlying chronic illness (immunologic diseases; neoplas-
tic disorders; renal, cardiac, hepatic, or hematologic diseases;
bronchodysplasia; Down syndrome; chronic otitis media with
effusion) or even a mild acute upper or lower respiratory tract
infection at the time of enrollment.
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The study protocol was approved by the ethics committees
of the pediatric departments in charge of health control of the
day-care centers and schools in each city, and written informed
consent was obtained from a parent or guardian of each child.
The questionnaires used to obtain demographic and clinical
characteristics of the enrolled children were completed by
trained reviewers in the presence of parents. The questions
included: 1) the duration of breast-feeding; 2) living condi-
tions (urban vs. rural); 3) information about previous day-care
attendance; 4) the number and age of family members; 5) birth
rank; 6) smoking habits of the family members living together;
7) the number and type of respiratory infections (including
rhinitis, tonsillitis, laryngitis, acute otitis media, sinusitis,
acute bronchitis, and pneumonia) during the previous 3
months; and 8) the number and type of antimicrobial drugs
administered during the previous 3 months. The information
was gathered without knowing the child’s carrier status.
Specimen Collection
Nasopharyngeal specimens were obtained by the same
trained investigator in each center on the basis of a previously
described and validated protocol (15): a Mini-Culturette (Bec-
ton Dickinson, Cockeysville, MD) extra-thin flexible wire
swab with its tip bent at an angle of approximately 30° was
inserted through the mouth and placed 1 to 1.5 inches into the
nasopharynx without touching the uvula or the tongue and
kept in place for at least 5 seconds. The children were not
allowed to eat or drink for 3 hours before specimen collection.
Microbiologic Procedures
The same microbiologic procedures were used by all of the
participating centers on the basis of previously validated
guidelines (15,16). The nasopharyngeal cultures were injected
into Stuart transport medium tubes (Venturi Transystem, Bres-
cia, Italy), which were sent to the microbiology laboratory of
the individual hospitals within 1-3 hours and immediately pro-
cessed. S. pneumoniae was isolated and identified using stan-
dard laboratory procedures (16). The strains were stored in
serum-glycerol freezing medium at -80°C, and the frozen sam-
ples were sent to the University of Genoa’s Institute of Micro-
biology to confirm their identity and to test their antimicrobial
susceptibility by Gram strain morphology, catalase reaction,
optochin susceptibility, and bile solubility. The strains were
serotyped by their quellung reaction with sera produced by the
Statens Seruminstitute (Copenhagen, Denmark) according to
established procedures (16). 
The strains susceptibility to penicillin, amoxicillin, amox-
icillin-clavulanic acid, cefotaxime, ceftriaxone, meropenem,
erythromycin, clarithromycin, azithromycin, tetracycline, tri-
methoprim-sulfamethoxazole, rifampicin, and chlorampheni-
col was tested using the agar dilution method described by the
National Committee for Clinical Laboratory Standards (16).
MICs of the antimicrobial drugs were determined using the
Sensititre microbroth incorporation technique with an inocu-
lum of approximately 105 CFU/mL in a medium of Mueller-
Hinton broth supplemented with saponin-lysed horse blood
and Factor V. Further details concerning the microbiologic
method we used are given in the article describing the results
of the Alexander Project (16). All of the laboratory work was
carried out in a blinded manner; susceptibility was tested by a
technician unaware of the serotypes, and the samples were
typed by a technician unaware of the susceptibility results.
Data Management and Analysis
The association between the characteristics of the children
and the carriage of S. pneumoniae was first analyzed by a
series of univariate analyses. Then, to control simultaneously
for the possible confounding effects of the different variables,
the risk of being an S. pneumoniae carrier was estimated by
multiple logistic regression analysis with stepwise variable
selection. The univariate and multivariate analyses of antibiot-
ics and antibiotic resistance assessed individual drugs as well
as all antibiotics together. In both analyses, the association was
expressed in odds ratios (OR) and 95% confidence intervals
(CI). Logistic regression analyses were made to evaluate the
correlates of the carriage of different S. pneumoniae strains.
On the basis of previous studies (12,17-19), strains 14, 6, 19,
18, 23, 9, 1, 7, 4, 5, 3, and 24 were considered invasive, and
strains 4, 6, 9, 14, 18, 19, and 23 covered by or cross-reactive
with the heptavalent vaccine. All of the reported p values are
two-sided and refer to a significance level of 0.05.
Results
Study Participation
The study involved 2,799 children, whose demographic
and clinical characteristics are shown in Table 1. Most of them
lived in an urban area, attended a large day-care center full-
time, belonged to small families, and had at least one respira-
tory tract infection in the previous 3 months. 
Recovery of S. pneumoniae from 
Nasopharyngeal Cultures
The pneumococcal carrier rate and the recovery of inva-
sive strains or strains covered by the heptavalent vaccine are
shown in Table 2. The total S. pneumoniae carrier rate was 242
(8.6%) out of 2,799, with no significant difference between the
age groups; the most common strains were 3 (11.6%), 19F
(11.2%), 23F (11.2%), 19A (10.7%), 6B (9.9%), and 14
(6.6%). Furthermore, 77.3% of the examined strains belonged
to invasive serogroups (with no significant difference between
the age groups) and 63.2% to serogroups covered by or cross-
reactive with the heptavalent pneumococcal vaccine. The
potential coverage related to the use of the heptavalent vaccine
was significantly higher in children ages <2 (73.1%) or 2-5
years (68.9%) than in those aged >5 years (51.2%: <2 vs. >5
years: p=0.040; 2-5 vs. >5 yrs: p=0.0008). The proportion of
invasive strains covered by the heptavalent vaccine was 153
(81.8%) of 187. Emerging Infectious Diseases  •  Vol. 8, No. 5, May 2002 481
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Susceptibility Patterns
The antibiotic resistance pattern of the S. pneumoniae
strains is shown in Table 3. Only 74 strains (30.6%) were sus-
ceptible to all of the antibiotics tested, 69 (28.5%) were resis-
tant to one antimicrobial agent, 70 (28.9%) were resistant to
two, and 29 (12.0%) to more than two. 
Only 22 S. pneumoniae isolates (9.1%) were penicillin-
resistant: 18 intermediately resistant (MIC 0.1-1.0 µg/mL) and
four fully resistant (MIC ≥ 2 µg/mL); the serogroups most resis-
tant were 9V (40.9%) and 23F (22.7%). Seventeen (77.3%) of
these penicillin-resistant strains were preventable by the hep-
tavalent pneumococcal conjugate vaccine; none of the five
strains not covered by the vaccine is usually considered inva-
sive. The incidence of penicillin resistance was significantly
higher in younger children (25.9% in children aged <2 years vs.
7.6% in those aged 2-5 years: p=0.024; 25.9% in children aged
<2 years vs. 5.9% in those aged >5 years: p=0.007).
Table 1. Characteristics of the 2,799 children tested for 
nasopharyngeal carriage of Streptococcus pneumoniae, 
13 Italian cities, April 15–June15, 2000
Characteristics
No. of children
(% of 2,799)
Male 1,459 (52.1)
Race (white) 2,760 (98.6)
Age
   <2 yrs 420 (15.0)
   2-5 yrs 1,389 (49.6)
   >5 yrs 990 (35.4)
Breast-feeding ≥ 3 mo. 1,477 (52.8)
Urban residence 2,537 (90.6)
Full-time child-care attendancea 2,571 (91.9)
No. of subjects in each child-care center 
   <20 927 (33.1)
   20-29 1,600 (57.2)
   >29 272 (9.7)
No. of siblings
   0 752 (26.9)
   1    1,450 (51.8)
   >2 597 (21.3)
First-born 1,366 (48.8)
Passive smoking 1,320 (47.2)
URTIs in the last 3 mo.b
   Rhinitis 1,759 (62.8)
   Tonsillitis 636 (22.7)
   Laryngitis 501 (17.9)
   Acute otitis media 558 (19.9)
   Acute sinusitis 174 (6.2)
LRTIs in the last 3 mo.b
   Acute bronchitis 579 (20.7)
   Pneumonia 167 (5.9)
   Antibiotic therapy in the last 3 mo.c
   Aminopenicillins 244 (8.7)
   Amoxicillin-clavulanate 214 (7.6)
   Macrolides 247 (8.8)
   Cephalosporins 507 (18.1)
   At least one antibiotic  1,032 (36.9)
a5-6 days/week, 6-8 hrs/day.
bOne or more episodes; URTIs = upper respiratory tract infections; LRTIs = lower respi-
ratory tract infections.
c One or more courses.
Table 2. Recovery of Streptococcus pneumoniae in the nasopharynx 
by age, 13 Italian cities, April 15–June 15, 2000 
Carriers
Age group (% of total/age group)
Total <2 yrs 2-5 yrs >5 yrs
Total/age group 420 1,389 990 2,799
Total carriers 26 (6.2) 132 (9.5) 84 (8.5) 242 (8.6)
Carriers of invasive 
strains
20 (74.1) 106 (81.5) 61 (71.2) 187 (77.3)
Carriers of strains 
covered by the hep-
tavalent vaccine
19 (73.1)a 91 (68.9)b 43 (51.2)a,b 153 (63.2)
aCarriers <2 yrs vs. carriers >5 yrs: p=0.040.
bCarriers 2-5 yrs vs. carriers >5 yrs: p=0.0008.
Table 3. Antibiotic resistance pattern of Streptococcus pneumoniae 
strains, 13 Italian cities, April 15–June 15, 2000
Antibiotic Resistant strains (%)
Penicillin 22 (9.1)
Amoxicillin 0
Amoxicillin-clavulanate 0
Cefotaxime 9 (3.7)
Ceftriaxone 8 (3.3)
Meropenem 12 (4.9)
Azithromycin 126 (52.1)
Clarithromycin 126 (52.1)
Erythromycin 126 (52.1)
Tetracyclin 74 (30.6)
Thrimethoprim-sulphamethoxazole 58 (23.9)
Rifampicin 0
Chloramphenicol 26 (10.7)RESEARCH
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Resistance to erythromycin, clarithromycin, and azithro-
mycin (MIC50 0.25, MIC90 ≥ 64) was very common (52.1%,
126 isolates); the most resistant serogroups were 6B (16.7%),
19F (15.9%), 14 (14.3%), and 19A (12.7%). Of these mac-
rolide-resistant strains, 94 (74.6%) were preventable by the
heptavalent pneumococcal conjugate vaccine; none of the 32
uncovered strains is usually considered invasive. Although no
significant association was found, the macrolide-resistant
strains were more often isolated in children aged <2 years
(60.4%) than in those ages 2-5 years (56.3%) or >5 years
(44.6%). Fourteen isolates (5.8%) were both penicillin and
macrolide resistant. 
Risk Factors for Nasopharyngeal 
Carriage of S. pneumoniae
Table 4 shows the results of the univariate analysis of the
potential risk factors for the nasopharyngeal carriage of S.
pneumoniae. One or more episodes of sinusitis in the previous
3 months was the only risk factor for total carrier status and the
carriage of both invasive strains and the strains covered by the
heptavalent vaccine. None of the other variables was signifi-
cantly associated with pneumococcal nasopharyngeal carriage,
regardless of the strain. Multivariate analysis also indicated at
least one episode of sinusitis in the previous 3 months as the
only risk factor for the nasopharyngeal carriage of S. pneumo-
niae (total carriers: OR 2.48; 95% CI 1.11-5.0; carriers of
Table 4. Univariate analysis of the variables potentially associated with the nasopharyngeal carriage of Streptococcus pneumoniae
Total carriers Carriers of invasive strains
Carriers of strains covered by the 
heptavalent vaccine
Risk factor ORsa 95%  CIb ORs 95% CI ORs 95% CI
Sex 1.0 0.8-1.4 0.9 0.7-1.4 0.9 0.7-1.3
Age, yrs
   2-5 0.7 0.1-1.7 1.3 0.8-2.3 1.5 0.9-2.7
   >5 1.5 0.9-2.5 0.9 0.5-1.6 1.1 0.6-1.9
Breast-feeding ≥ 3 mo. 0.9 0.6-1.4 1.0 0.6-1.7 1.1 0.7-1.7
Urban residence 0.8 0.1-2.2 1.2 0.6-2.6 1.5 0.7-2.9
Full-time day-care attenance 0.4 0.1-1.5 0.8 0.6-1.2 1.0 0.7-1.4
Child-care center ≥ 20 subjects 0.9 0.6-1.3 1.2 0.8-1.9 1.2 0.8-1.9
At least one sibling 0.9 0.7-1.3 0.7 0.4-1.2 0.7 0.4-1.3
First-born 1.0 0.8-1.4 1.1 0.8-1.6 1.1 0.8-1.6
Passive smoking 1.0 0.7-1.3 1.0 0.7-1.4 1.0 0.7-1.4
At least one URTIcin the previous 3 mo. 
   Rhinitis 0.9 0.7-1.3 1.0 0.7-1.5 1.0 0.7-1.5
   Tonsillitis 0.8 0.6-1.3 0.9 0.6-1.5 1.0 0.6-1.5
   Laryngitis 0.6 0.3-1.1 0.8 0.5-1.5 0.8 0.4-1.5
   Acute otitis media  1.3 0.9-1.9 1.5 0.9-2.3 1.4 0.9-2.2
   Acute  sinusitis 2.3 1.1-4.6d 3.1 1.4-6.4d 3.3 1.6-6.9 d
LRTIse in the previous 3 mo.
   Acute bronchitis 0.7 0.4-1.1 0.6 0.3-1.1 0.6 0.4-1.1
   Pneumonia 0.8 0.2-2.6 0.4 0.1-3.1 0.9 0.2-3.7
   Antibiotic therapy in the previous 3 mo.
   Aminopenicillins  0.9 0.6-1.5 1.0 0.5-1.8 1.0 0.5-1.8
   Amoxicillin-clavulanate 0.8 0.4-1.3 0.7 0.3-1.5 0.8 0.4-1.5
   Macrolides 0.6 0.3-1.1 0.8 0.4-1.6 0.7 0.4-1.5
   Cephalosporins 0.9 0.6-1.3 0.8 0.5-1.3 0.9 0.6-1.5
   At least one antibiotic 0.8 0.7-1.2 1.0 0.7-1.4 1.0 0.7-1.4
aOR = odds ratio.
b95%CI= confidence interval.
c URTIs= upper respiratory tract infections.
d p<0.05.
e LRTIs=lower respiratory tract infections.Emerging Infectious Diseases  •  Vol. 8, No. 5, May 2002 483
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invasive strains: OR 3.04; 95% CI 1.23-6.53; carriers of
strains covered by the heptavalent vaccine: OR 3.30; 95% CI
1.41-6.83).
In terms of antibiotic resistance, univariate analysis identi-
fied one or more episodes of acute otitis media in the previous
3 months as the only risk factor (OR, 2.8; 95% CI 1.2-6.8) and
an age >5 years as a protective factor (OR, 0.3; 95% CI, 0.1-
1.0) for the carriage of penicillin-resistant S. pneumoniae.
Multivariate analysis confirmed the role of a previous history
of acute otitis media (OR 2.7; 95% CI 1.0-6.6). Neither
univariate or multivariate analysis identified an association
between the carriage of macrolide-resistant strains and any
risk or protective factor. 
Discussion
S. pneumoniae was carried by 8.6% of the 2,799 healthy
children. Possible reasons for this low prevalence, similar to
that previously reported by us (15), include the fact that the
survey only included healthy children, the subjects were
enrolled for a very short time, winter (a period of frequent res-
piratory illness) was not the season of enrollment, the large
sample prevented any focus on specific situations, and the fact
that human genetic traits may play a role (15,17,20). Further-
more, although a sampling or laboratory error is unlikely
because all of the investigators were carefully pretrained and
the microbiologic procedures were monitored throughout the
study, some continuing colonization titers may have been
below the sensitivity threshold of the culture method (13).
The serotypes most frequently colonizing our healthy pop-
ulation (3, 19F, 23F, 19A, 6B, and 14) were those commonly
involved in invasive pneumococcal diseases (12,17-19,21),
highlighting the importance of nasopharyngeal colonization in
the development of serious community infections. 
The low rate of penicillin resistance (9.1%) and the high
rate of macrolide resistance (52.1%) detected in our study pop-
ulation are in contrast to the data reported in other countries
(22-25) but consistent with previous Italian reports regarding
adults and children with lower respiratory tract infections and
invasive diseases (19,26,27). Comparison of the present data
with those coming from our previous survey of a similar popu-
lation of healthy subjects revealed an increased prevalence of
antibiotic-resistant pneumococci, especially in children ages
<2 years (15). As in other studies, we found that resistance to
penicillin was associated with serotypes 9V and 23F, whereas
resistance to macrolides was related to a wide range of sero-
types (particularly 6B, 19F, 14, and 19A) (19,26,27). 
Univariate and multivariate analyses indicate that infec-
tions of the nasal sinuses and the middle ear may favor S.
pneumoniae carriage and may play a role in the spread of the
organisms. However, considering that the data on the charac-
teristics of our study population were obtained from parental
recollection, the role of the different risk factors in pneumo-
coccal colonization needs to be further confirmed. The protec-
tive effect of an age of >5 years on the carriage of penicillin-
resistant strains is in agreement with other published data (17).
As we have previously observed (15), but unlike other
authors’ findings (10,28), nasopharyngeal carriage of S. pneu-
moniae and antibiotic use per se or the type of drug used in the
previous 3 months were not related. In our previous survey
(15), we found that having one or more older siblings and a
history of full-time day-care attendance were risk factors for
the nasopharyngeal carriage of S. pneumoniae, whereas living
in a rural area was a protective factor.  The differences
observed in this study may be because of changes in the epide-
miologic characteristics of pneumococcal carriage in Italy and
confirm the importance of constant local surveillance. 
Our data on the efficacy of the heptavalent pneumococcal
conjugate vaccine indicate that it could have a considerable
impact on the incidence of nasopharyngeal carriage and a
major effect on invasive and antibiotic-resistant pneumococcal
diseases, especially in the first years of life. 
In conclusion, our study shows that, although nasopharyn-
geal carriage is low in healthy children, the most common cir-
culating serotypes are invasive and antibiotic resistant. No risk
factor other than sinusitis and acute otitis media seems to be
related to pneumococcal colonization and to the carriage of
penicillin-resistant S. pneumoniae, respectively. The fact that
most isolated strains are covered by the heptavalent conjugate
vaccine, especially in the first years of life, suggests that its
broader use could reduce the incidence of pneumococcal
disease.
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